Want to see HK:2453 full AI Analyst Report?
Concord Healthcare Group Co., Ltd. Class H (2453) AI Stock Analysis
Concord Healthcare Group Co., Ltd. Class H
(HKEX:2453)
The score is primarily constrained by persistent losses, negative cash generation, and leverage. Weak technical momentum and an unprofitable valuation provide additional downside pressure, resulting in a very low overall stock score.
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 489.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 194.73K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 0.93
- Revenue Growth
- 47.93%
- EPS Growth
- 65.94%
- Country
- Hong Kong
- Employees
- 592
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of m...
How the Company Makes Money
Concord Healthcare Group primarily generates revenue through a combination of service fees and product-related income tied to oncology and hospital-based clinical infrastructure. A key revenue stream is the provision of management and operational ser...
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
Summary
Financial performance is very weak: the provided income statement, balance sheet, and cash flow scores are 25, 35, and 20. Revenue and equity improved, but substantial net losses, negative operating and free cash flow, and high leverage keep this component at the minimum score.
Income Statement
25NegativeBalance Sheet
35NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.04M | 448.02M | 388.31M | 538.65M | 472.17M | 470.50M |
| Gross Profit | 102.69M | 31.12M | -67.25M | -65.09M | -197.46M | -92.76M |
| EBITDA | 21.82M | -60.07M | -194.46M | -172.58M | -321.75M | -326.04M |
| Net Income | -154.94M | -249.96M | -443.22M | -373.09M | -541.40M | -816.59M |
Balance Sheet | ||||||
| Total Assets | 5.66B | 5.79B | 5.91B | 5.24B | 6.08B | 6.66B |
| Cash, Cash Equivalents and Short-Term Investments | 161.74M | 319.01M | 337.12M | 49.23M | 136.06M | 136.09M |
| Total Debt | 3.06B | 3.09B | 3.21B | 2.64B | 2.85B | 2.48B |
| Total Liabilities | 3.73B | 3.76B | 4.01B | 3.37B | 3.84B | 8.08B |
| Stockholders Equity | 1.75B | 1.83B | 1.65B | 1.60B | 1.69B | -1.56B |
Cash Flow | ||||||
| Free Cash Flow | -207.18M | -259.95M | -500.12M | 18.11M | -175.66M | -584.24M |
| Operating Cash Flow | -196.67M | -113.08M | -185.96M | 201.85M | -93.64M | 45.87M |
| Investing Cash Flow | 54.01M | 110.91M | -668.09M | -182.34M | -100.33M | -945.04M |
| Financing Cash Flow | 85.65M | 92.10M | 1.02B | -105.43M | 184.37M | 505.06M |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2453, the sentiment is Negative. The current price of 0.63 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.73, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.31 is Neutral, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2453.
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
Overall Rating
HK:330966Neutral
HK:607862Neutral
HK:386954Neutral
HK:663948Neutral
HK:388641Neutral- HK:245338Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3309 | 66Neutral | HKD 1.05B | 10.10 | 5.57% | 2.35% | 4.75% | ― |
| HK:6078 | 62Neutral | HKD 5.84B | 27.81 | 2.55% | ― | 1.59% | -58.55% |
| HK:3869 | 54Neutral | HKD 467.79M | -143.62 | -0.41% | ― | 3.16% | -101.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6639 | 48Neutral | HKD 1.03B | 31.06 | 1.27% | ― | ― | ― |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
| HK:2453 | 38Underperform | HKD 489.79M | -2.69 | -8.65% | ― | 47.93% | 65.94% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2453 | Concord Healthcare Group Co., Ltd. Class H | 0.63 | -1.81 | -74.39% | |
| HK:3309 | C-MER Eye Care Holdings Limited | 0.85 | -0.91 | -51.81% | |
| HK:3869 | Hospital Corporation of China Ltd | 3.38 | -2.61 | -43.49% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% | |
| HK:6078 | Hygeia Healthcare Holdings Co., Ltd. | 9.51 | -3.88 | -29.01% | |
| HK:6639 | Arrail Group Ltd. | 1.83 | -0.09 | -4.74% |
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Controlling Shareholder Revises H-Share Pledge for Smaller Loan
Concord Healthcare Group Co., Ltd. has disclosed that its controlling shareholder Beijing Concord Medical Technology Co., Ltd. has adjusted a major share pledge arrangement involving its H shares in the company. Beijing Concord previously pledged 35,...
Concord Healthcare’s Controlling Shareholder Renews Share Pledge for Smaller Loan Facility
Concord Healthcare Group Co., Ltd. has disclosed that its controlling shareholder, Shanghai Medstar, has fully released a previous pledge over domestic shares linked to a RMB500 million loan facility. On the same day, Shanghai Medstar entered into a...
Concord Healthcare Narrows Loss as Hospital Revenue Surges in First Half 2026
Concord Healthcare Group reported a sharp improvement in operating performance for the six months ended June 30, 2026, driven by strong growth in its core hospital operations. Revenue rose 34.2% year-on-year to RMB269.6 million, with hospital operati...
Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend
Concord Healthcare Group Co., Ltd., a PRC-based healthcare group listed in Hong Kong, operates through multiple subsidiaries to deliver medical and healthcare services, with governance overseen by a board comprising executive, non-executive, independ...
Concord Healthcare Flags Surging First-Half 2026 Profit on Proton Therapy Growth
Concord Healthcare Group has issued a profit alert indicating a sharp improvement in its financial performance for the six months ended June 30, 2026, based on preliminary unaudited figures. The group expects revenue of about RMB260 million to RMB280...
Concord Healthcare Seals Uzbekistan PPP for Gamma Knife Cancer Centre
Concord Healthcare Group has signed a public-private partnership agreement with Uzbekistan’s Ministry of Health to fully invest in and operate a Gamma Knife stereotactic radiosurgery centre at the Tashkent National Medical Centre for a 15-year...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026